Intercept Pharmaceuticals delivered a bad news-good news punch over the weekend about its lead drug.
written on 17.03.2014
Intercept's lead drug boasts success in PhIII after worrisome side-effects disclosure
Latest Reports
New Era in Access to Rare Disease Drugs in Canada
Durhane Wong-Rieger is the President & CEO of the Canadian Organization for Rare Disorders (CORD). In her first…
“Canada Needs to do Better in Supporting Innovative Biopharma”
Brian Hilberdink, President of Novo Nordisk Canada, calls for the Canadian government to encourage and invest in…
Success in Rare Disease Patient Advocacy — What it Takes
After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica Weldon founded Bridge the…